Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
ETAA1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ETAA1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
Epratuzumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Epratuzumab: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ESYT3 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ESYT3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ESYT2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ESYT2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
Acetylcysteine/bromelain(Mucpharm) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Acetylcysteine/bromelain(Mucpharm): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ESYT1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ESYT1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ESX1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ESX1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
Alisertib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Alisertib: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ESS2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ESS2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
Acarbose/Orlistat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Acarbose/Orlistat: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ESRRG Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ESRRG, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
Pregabalin/Riluzole Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Pregabalin/Riluzole: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.